NASDAQ:CNCE
Delisted
Concert Pharmaceuticals Stock News
$8.37
+0 (+0%)
At Close: May 30, 2023
Concert Pharmaceuticals, Inc (CNCE) CEO Roger Tung on Q3 2019 Results - Earnings Call Transcript
12:00am, Monday, 11'th Nov 2019Concert Pharmaceuticals (CNCE) Investor Presentation - Slideshow
12:00am, Friday, 08'th Nov 2019Concert Pharmaceuticals Q3 EPS $(0.72) Beats $(0.83) Estimate, Sales $10K May Not Compare To $60K Estimate
12:00am, Thursday, 07'th Nov 2019Merrill Raises Payouts in Retirement Transition Plan, Tweaks “Inheritor” Payoffs - AdvisorHub
07:15pm, Wednesday, 06'th Nov 2019
In a move to keep senior brokers’ clients and compete with UBS and Morgan Stanley, Merrill adds 5 to 75 percentage points to payouts of those who transition their books internally.
Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for
12:00am, Thursday, 31'st Oct 2019Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV 2019
12:00am, Saturday, 12'th Oct 2019The Week Ahead In Biotech: Pfenex And Clinuvel On The Radar Ahead of FDA Decisions, 2 IPOs On Deck
12:00am, Sunday, 06'th Oct 2019Concert Pharmaceuticals (CNCE) Investor Presentation - Slideshow
12:00am, Friday, 04'th Oct 2019Toyota RAV4 Review | The only RAV4 review you need to read
12:34am, Thursday, 03'rd Oct 2019
The RAV4 is a near-perfect execution of the family SUV. Car reviewers, by their own admissions, had to get real fastidious to find fault with it.
